Stockholm - Delayed Quote • SEK
Moberg Pharma AB (publ) (MOB.ST)
At close: 5:29 PM GMT+2
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Anna Ljung BA, M.Sc. | Chief Executive Officer | 2.93M | -- | 1980 |
| Ms. Marie Moberg | Co-Founder | 193.7k | -- | -- |
| Mr. Mark Beveridge | Vice President of Finance | -- | -- | 1978 |
| Dr. Christina Erixon | Head of Pharmaceutical Development & Operations | -- | -- | 1970 |
| Gunilla Wengström | Senior Director of Sales & Marketing | -- | -- | -- |
| Anders Broijersen M.D., Ph.D. | Chief Medical Officer | -- | -- | 1964 |
| Mr. Robert Ehrl | Head of Supply | -- | -- | 1967 |
Moberg Pharma AB (publ)
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 10
Description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. The company develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Corporate Governance
Moberg Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Nov 04, 2019Ex-Dividend Date
Upcoming Events
May 07, 2024
Moberg Pharma AB (publ) Earnings Call
Related Tickers
CPH.TO Cipher Pharmaceuticals Inc.
8.53
+0.24%
CPHRF Cipher Pharmaceuticals Inc.
6.25
+0.32%
PETQ PetIQ, Inc.
16.11
-2.54%
EVO Evotec SE
5.05
-3.54%
LFCR Lifecore Biomedical, Inc.
6.16
-2.69%
CANB.V CanadaBis Capital Inc.
0.0750
-6.25%
SBBC.V Simply Better Brands Corp.
0.3600
+2.86%
GRUSF Grown Rogue International Inc.
0.7077
+8.54%
GLASF Glass House Brands Inc.
8.52
-1.62%
MDP.TO Medexus Pharmaceuticals Inc.
1.8200
+4.60%